Beilu Pharmaceutical's Iohexol Injection Receives Marketing Authorization in Hungary

Recently, Beijing Beilu Pharmaceutical Co., Ltd. received the "Marketing Authorization" (MA) for its Iohexol Injection issued by Hungarian National Institute of Pharmacy and Nutrition (OGYÉl). This is another EU member state approval for the product after it was approved for marketing authorization in the Netherlands.

The Hungarian approval of Iohexol Injection will further accelerate Beilu Pharma’s global market expansion, enhance the international competitiveness of its contrast media products, and lay a solid foundation for sustainable growth in overseas markets, which is expected to have a positive impact on the company’s operations.

In recent years, Beilu early overseas market expansion work has achieved remarkable results. The company's exported products are mainly Contrast agent formulations and APIs, and its business covers markets such as South America, Africa, and Asia.

--In Contrast agent formulation, the entire line of products has been successfully exported and achieved a substantial revenue growth;

--In APIs, Beilu’s subsidiary Hichi Pharm continues to expand its Iodinated APIs , while its Cangzhou facility has gradually internationalized its gadolinium-based APIs.

With the completion of the EU GMP certification and Brazil's ANVISA GMP compliance certification, the internationalization of the company's contrast agent products is expected to accelerate further.